ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2023
The Australia Smoking and Vaping Model: The Potential Impact of Increasing Access to Nicotine Vaping Products.
Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Trends and cross-country inequalities in the global burden of gastrointestinal cancers attributable to smoking, 1990-2021: A secondary dataset analysis of GBD Study 2021.Tobacco induced diseases · 2026Article
- Potential impact of e-cigarettes on life-years lost from conventional smoking in Ukraine, a replication study.Central European journal of public health · 2025Article
- Association between electronic cigarette use and respiratory outcomes among people with no established smoking history: a comprehensive review and critical appraisal.Internal and emergency medicine · 2025Review
- Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021.Scientific reports · 2025Observational
- Pharmacists' Perspectives on Nicotine Vaping Products (NVPs) for Smoking Cessation in Australia: A Qualitative Analysis.Pharmacy (Basel, Switzerland) · 2025Article
- Nicotine pouches: a narrative review of the existing literature.Frontiers in public health · 2025Review
- Global burden of bladder cancer attributable to smoking in 204 countries and territories, 1990-2019.Heliyon · 2024Article
- The potential impact of removing a ban on electronic nicotine delivery systems using the Mexico smoking and vaping model (SAVM).medRxiv : the preprint server for health sciences · 2024Article
- The smoking and vaping model, A user-friendly model for examining the country-specific impact of nicotine VAPING product use: application to Germany.BMC public health · 2023Article
- Summary and Concluding Remarks: Patterns of Birth Cohort‒Specific Smoking Histories.American journal of preventive medicine · 2023Article
- Reasons to decrease or stop nicotine and tobacco use among adults and association with MPOWER scores in twenty-one middle- and high-income countries, 2019-2020.Tobacco prevention & cessation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundWe model the potential impact of relaxing current nicotine vaping product (NVP) restrictions on public health in Australia. AIMS AND
methodsA Restricted NVP Scenario was first developed to project current smoking and vaping rates, where a U.S. smoking model was calibrated to recent Australian trends. To model less restrictive NVP policies, a Permissive NVP Scenario applied rates of switching from smoking to vaping, initiation into NVP and cigarette use, and cessation from smoking and vaping based on U.S. trends. The model measures vaping risk relative to the excess mortality rate of smoking. The public health impacts are measured as the difference between smoking- and vaping-attributable deaths (SVADs) and life years lost (LYLs) in the Restricted and Permissive NVP Scenarios. Sensitivity analysis is conducted regarding the NVP excess risk and other factors.
resultsAssuming an NVP excess risk of 5% that of smoking, 104.2 thousand SVADs (7.7% reduction) and 2.05 million LYLs (17.3% reduction) are averted during 2017-2080 in the Permissive NVP Scenario compared to the Restricted NVP Scenario. Assuming 40% NVP excess risk, 70 thousand SVADs and 1.2 million LYLs are averted. The impact is sensitive to the rate at which smokers switch to NVPs and quit smoking, and relatively insensitive to the smoking initiation and NVP initiation and cessation rates.
conclusionsThe model suggests the potential for public health gains to be achieved by relaxing NVP access regulations. However, the model would benefit from better information regarding the impact of NVPs on smoking under a relaxation of current restrictions. IMPLICATIONS: Australia has implemented a strong array of cigarette-oriented policies, but has restricted access to NVPs. The Smoking and Vaping Model offers a framework for modeling hypothetical policy scenarios. The Australian model shows the potential for public health gains by maintaining cigarette-oriented policies while relaxing the current restrictive NVP policy. Modeling results under a permissive NVP policy are particularly sensitive to the estimated rates of smoking cessation and switching to vaping, which are not well established and will likely depend on past and future cigarette-oriented policies and the specific NVP policies implemented in Australia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.